Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Covington
Chinese Patent Office
QuintilesIMS
US Army
Deloitte
AstraZeneca
Harvard Business School
McKesson

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,372,872

« Back to Dashboard

Which drugs does patent 8,372,872 protect, and when does it expire?

Patent 8,372,872 protects ULORIC and is included in one NDA.

This patent has thirteen patent family members in eleven countries.
Summary for Patent: 8,372,872
Title:Methods for concomitant treatment of theophylline and febuxostat
Abstract: Co-administration of febuxostat and theophylline to a hyperuricemic patient suffering from gout is disclosed.
Inventor(s): Gunawardhana; Lhanoo (Pleasant Prairie, WI), Naik; Himanshu (Evanston, IL), Tsai; Max (Highland Park, IL)
Assignee: Takeda Pharmaceuticals U.S.A., Inc. (Deerfield, IL)
Application Number:13/295,696
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,372,872
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,372,872

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-001 Feb 13, 2009 RX Yes No ➤ Sign Up ➤ Sign Up USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE ➤ Sign Up
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-002 Feb 13, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,372,872

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,107,912 Methods for concomitant treatment of theophylline and febuxostat ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Citi
Express Scripts
Covington
Healthtrust
US Department of Justice
Deloitte
Cipla
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.